Fundz
New|Fundz now works inside Claude2 min

Timing. Relevance. Relationships.

Fundz is the only platform that reads more than a dozen real‑time signals all day, every day, so you know about new funding, new executives and new contracts within minutes of them happening, not days or weeks later like the databases you’re used to. It then combines the signals on each company, scores every company against what you offer, and weaves in your own network, so you discover new accounts first and work existing ones better.

Each morning you get the ones worth your time right now: who to reach, why now, and who you already know there. Now it answers in Claude too: ask for today’s leads, then write the note in the same window.

Trusted by

OracleSnowflakeCloudflareLinkedInGoogleSalesforce
4.8/5 on G2· Since 2015

OMass Therapeutics secures €275 million in an oversubscribed Series C round to advance its small-molecule therapies. The round was co-led by Bain Capital Life Sciences, Forbion, and Novo Holdings.

PRIVATEOct 16, 2026

Amount Raised

€275 Million

Round Type

Series C

United KingdomBiotechnologyTherapeutics

Investors

University Of OxfordBritish Business BankSanofi VenturesNorthpond VenturesGVOxford Science EnterprisesSynconaJefferson Life SciencesSV Health InvestorsJanus Henderson InvestorsNovo HoldingsForbionBain Capital Life Sciences

Description

OMass Therapeutics, a UK BioTech company, has successfully secured €275 million in a Series C funding round. The funding will help bring their novel small-molecule therapies closer to patients. New and existing investors participated in this oversubscribed round. This financing enables OMass to advance its clinical developments and expand its portfolio of medicines.

Company Information

Company

OMass Therapeutics

Location

United Kingdom

About

OMass Therapeutics is a UK biotechnology company focused on developing small molecule therapeutics to tackle highly validated target ecosystems. Founded in 2016, the company was developed from research conducted in Professor Dame Carol Robinson’s lab at the University of Oxford. OMass leverages its proprietary OdyssION drug discovery platform, combining advanced techniques in mass spectrometry and biochemistry to create differentiated medicines. The company's lead program, OMS1620, aims to address significant unmet needs in endocrinology and immunology.

Fundz sees it the moment OMass Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Predictive Intelligence
Strategic

ML-powered predictions for OMass Therapeutics's next move

See what Strategic adds

OMass Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.